Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                IVD Regulatory Assistance

IVD Regulatory Assistance

                        Clinical Laboratory Improvement Amendments (CLIA)
          CLIA Categorizations
          CLIA Waiver by Application
          Public Databases
          Overview of IVD Regulation Home
          Medical Devices
          Device Advice: Comprehensive Regulatory Assistance
          IVD Regulatory Assistance
          Suggested Analytical Testing Protocol for In Vitro Diagnostic Devices Manufactured with Heparin Contaminated With Oversulfated Chondroitin SulfateIVD Regulatory Assistance Suggested Analytical Testing Protocol for In Vitro Diagnostic Devices Manufactured with Heparin Contaminated With Oversulfated Chondroitin Sulfate
  
  	
    Share
    Post
    Linkedin

    Email
    PrintA number of in vitro diagnostic devices, such as heparinized blood collection tubes/dispensers and diagnostic assay kits/reagents, might have been manufactured using heparin contaminated with oversulfated chondroitin sulfate (OSCS). To determine whether analytical performance is affected by this contaminant, the following analytical testing protocol should be taken into consideration. This protocol is offered as one possible approach toward answering questions about the effect of contaminated heparin on the in vitro diagnostic devices described above.

Determine which specific device(s) containing or utilizing heparin in their manufacturing. If none, no further action is needed.
	If such device(s) exists, determine those manufactured with the highest level of OSCS-contaminated heparin, and perform the following analytical testing under a clearly written protocol: 
	2.1. For blood collection tubes/dispensers:Identify the analytes that can be assayed in various clinical laboratory settings (e.g., chemistry, hematology, immunology, microbiology, toxicology) using blood specimens collected in these tubes/dispensers.

	Select at random tubes/dispensers containing contaminated heparin from the same lot. Collect paired blood samples from 40 volunteer subjects in tubes/dispensers containing contaminated and uncontaminated heparin as controls, respectively.

	Perform comparative analytical testing of the concerned analytes, preferably in duplicate, using one or more common analytical platforms.

	For clinically significant analytes that may be physiologically undetectable or exist in relatively low levels in healthy subjects, and for which no clinical samples are readily available (e.g., troponin, creatine kinase-MB), perform spiking tests with a range of concentrations (e.g., low, intermediate, and high) of the analyte(s).

	Retain left-over samples, if possible, for additional testing at a later time, should that become necessary.
		2.2. For diagnostic kits/reagents:
		Select at random five to ten kits/reagents manufactured with contaminated heparin, and two or more retained kits/reagents from a lot known to be free of contaminated heparin as control.Perform comparative testing between contaminated and non-contaminated kits of the concerned analyte(s) using either quality control materials, or spiked blood samples (whole blood, plasma, and/or serum, as appropriate), covering a wide range of concentrations (e.g., low, intermediate, and high) of the analyte(s). Test the analyte(s), preferably in duplicate, at each concentration.
			If no retained control kits/reagents are available, use appropriate blood samples spiked with known concentrations of the analyte(s) for a recovery study.
		2.3. For accessory reagent(s)/components (e.g., flushing, cleaning, or rinse solution) 
		Identify if the accessory reagent /component influences any test result. If so, perform applicable testing as described in section 2.2 above.
	Examine analytical comparison data for evidence of potential analytical interference (e.g., positive or negative bias) by OSCS using appropriate descriptive statistics and statistical tests. Investigate further any pattern of interference to identify the root cause, and to establish appropriate actions to mitigate the risk.
	Adhere to applicable institutional rules (e.g., informed consent, IRB, HIPPAA Privacy Rule) governing testing involving human subjects. Retain all records (e.g., calibrations, quality controls, instrument maintenance, source data) as described in the *E6 Good Clinical Practice: Consolidated Guidance*.The points of contact in this office are Eugene Reilly, MS (eugene.reilly@fda.hhs.gov), or Tara Goldman, MS (tara.goldman@fda.hhs.gov).

Additional Guidance

E6 Good Clinical Practice: Consolidated Guideline
	Information on Heparin

                                                                                  Content current as of:
      03/22/2018
              
              
Regulated Product(s)
		 Medical Devices
			  			     			  			     Radiation-Emitting ProductsIVD Regulatory Assistance

          
                        Clinical Laboratory Improvement Amendments (CLIA)
          CLIA Categorizations
          CLIA Waiver by Application
          Public Databases
          Overview of IVD Regulation
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop